CN103110825A - Medicinal composition for treating diabetes and preparation method thereof - Google Patents
Medicinal composition for treating diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN103110825A CN103110825A CN2013100534377A CN201310053437A CN103110825A CN 103110825 A CN103110825 A CN 103110825A CN 2013100534377 A CN2013100534377 A CN 2013100534377A CN 201310053437 A CN201310053437 A CN 201310053437A CN 103110825 A CN103110825 A CN 103110825A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- weight portion
- herba dendrobii
- ramulus mori
- fructus corni
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for treating diabetes and a preparation method thereof. The composition comprises mulberry twig, mantis egg-case, cornel and dendrobe. The medicinal composition disclosed by the invention is prepared through the steps such as decocting, filtering, concentrating, drying and the like, and can be prepared into clinically acceptable tablets, capsules, granules, pills or oral liquids by adding conventional auxiliary materials. The medicinal composition disclosed by the invention has the effects of blood sugar reduction, blood fat reduction, blood rheology change, oxidation resistance and the like, has favorable treatment action and remarkable effect on diabetes, and has no toxic or side effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of diabetes.
Background technology
Diabetes are the commonly encountered diseases that is caused by the h and E factor interaction, and are clinical take hyperglycemia as outstanding feature, and common sympton has polydipsia, polyuria, polyphagia and becomes thin etc.Diabetes can cause the infringement of health multisystem.Cause that the absolute or relative hyposecretion of insulin and target tissue cell reduce insulin sensitivity, cause a series of metabolism disorder syndromes such as protein, fat, power and water Xie Zhi, wherein take hyperglycemia as outstanding feature.The multiple teenager of being born in of type i diabetes relies on exogenous insulin and replenishes to sustain life; During type ii diabetes is more common in, the old people, show as body responsive not to insulin, i.e. insulin resistant.At present the medicine for the treatment of diabetes is a lot, Western medicine especially, but side effect is large.The Chinese patent medicine effect is remarkable not.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition for the treatment of diabetes.
The object of the invention also is to provide a kind of preparation method for the treatment of the pharmaceutical composition of diabetes.
The present invention is achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of:
Ramulus Mori 20-60 weight portion Ootheca Mantidis 40-120 weight portion
Fructus Corni 20-60 weight portion Herba Dendrobii 10-30 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Ramulus Mori 40 weight portion Ootheca Mantidis 80 weight portions
Fructus Corni 40 weight portion Herba Dendrobii 20 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Ramulus Mori 25 weight portion Ootheca Mantidis 115 weight portions
Fructus Corni 25 weight portion Herba Dendrobii 28 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Ramulus Mori 55 weight portion Ootheca Mantidis 45 weight portions
Fructus Corni 55 weight portion Herba Dendrobii 12 weight portions.
Pharmaceutical composition of the present invention adds conventional adjuvant to make the tablet of clinical acceptance, capsule, granule, pill or oral liquid according to common process.
The preparation method of pharmaceutical composition of the present invention is: Ramulus Mori, Fructus Corni and Herba Dendrobii are added water 10-20 doubly measure, soaked 24-48 hour; With slow fire boiling 1-3 time, decocted 1-3 hour at every turn, medicinal liquid is leached, collect standby; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, fried 5-10 minute with slow fire, wear into fine powder and above-mentioned thick paste mixing, low-temperature bake 5-15 hour, the powder that gets dry extract added conventional adjuvant pharmaceutically to make tablet, capsule, granule, oral liquid, injection or pill dried cream powder.
The preferred preparation method of pharmaceutical composition of the present invention is: Ramulus Mori, Fructus Corni and Herba Dendrobii are added 15 times of amounts of water, soaked 36 hours; With slow fire boiling 2 times, decocted for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge the secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, fried 8 minutes with slow fire, wear into fine powder and above-mentioned thick paste mixing, low-temperature bake 10 hours, the powder that gets dry extract adds dried cream powder 75% ethanol of 2 times of amounts again, be evaporated to the thick paste shape, add 5 times the amount Icing Sugar, add 70% ethanol a little, make soft material, crossing 14 mesh sieves granulates, wet granular is dry under 50 ℃, and dry grain is after 14 mesh sieve granulate, granulation agent.
Pharmaceutical composition of the present invention has the effects such as blood sugar lowering, blood fat reducing, the change of change blood flow and antioxidation, and the treatment diabetes are had good therapeutical effect, and effect is remarkable, has no side effect.
Following experimental example is used for further illustrating the present invention, but is not limited to the present invention.
One, experimental example
1, clinical observation
Treatment group 1 anthology invention Granules in Treating diabetics 50 examples, male's 20 examples wherein, women's 30 examples.
Treatment group 2 anthology invention tablet in treatment diabetics 50 examples, male's 20 examples wherein, women's 30 examples.
Treatment group 3 anthology invention capsules treatments diabetics 50 examples, male's 20 examples wherein, women's 30 examples.
Matched group is selected the Ramulus Mori granule, is produced treatment diabetics 50 examples, male's 20 examples wherein, women's 30 examples by Qingdao Haier Pharmaceutical Co., Ltd.
Above patient all meets ADA diabetes diagnosis standard in 2010.
2, medicament selection
Treatment group 1: granule of the present invention (according to embodiment 1 method preparation), treat three courses for the treatment of (10 days courses for the treatment of), the 3g/ bag, one day 3 times, one time 1 bag.
Treatment group 2: tablet of the present invention (according to embodiment 2 methods preparations), treat three courses for the treatment of (10 days courses for the treatment of), the 0.3g/ sheet, one day 3 times, one time 1.
Treatment group 3: capsule of the present invention (according to embodiment 3 methods preparations), treat three courses for the treatment of (10 days courses for the treatment of), the 0.3g/ grain, one day 3 times, one time 1.
Matched group: the Ramulus Mori granule, produced by Qingdao Haier Pharmaceutical Co., Ltd, treat three courses for the treatment of (10 days courses for the treatment of), the 3g/ bag, 3 times on the one, one time 1 bag.
3, diagnostic criteria
ADA diabetes diagnosis standard in 2010:
1, glycosated Hb A 1c 〉=6.5%.
2, fasting glucose FPG 〉=7.0mmol/l.Be defined as on an empty stomach the interior empty calory absorption of 8h at least.
3,2h blood glucose 〉=11.1mmol/l during the oral glucose tolerance test.
4, at the patient with typical hyperglycemia or hyperglycemia crisis symptom, random blood sugar 〉=11.1mmol/l.
5, without clear and definite hyperglycemia the time, should come confirmation standard 1～3 by duplicate detection.
4, criterion of therapeutical effect
Produce effects: after treatment, symptom disappears substantially, fasting glucose＜7.2mmol/L, (130mg/dl), 2 hours blood glucoses＜8.3mmol/L(150mg/dl) after the meal, twenty-four-hour urine sugar total amount＜10.0g, or blood glucose, twenty-four-hour urine sugar total amount are treated front decline more than 30%.
Effectively: after treatment, symptom is obviously improved, fasting glucose＜8.3mmol/L(150mg/dl), 2 hours blood glucoses＜10.0mmol/L(180mg/dl) after the meal, twenty-four-hour urine sugar total amount＜25.0g, or blood glucose, twenty-four-hour urine sugar total amount are treated front decline more than 10%.
Invalid: after treatment, symptom is without obvious improvement, and blood glucose, glucose in urine descend and do not reach above-mentioned standard.
Table 1 treatment group 1 Clinical Laboratory efficacy evaluation (n=50)
Table 2 treatment group 2 Clinical Laboratory efficacy evaluations (n=50)
Table 3 treatment group 3 Clinical Laboratory efficacy evaluations (n=50)
Table 4 matched group Clinical Laboratory efficacy evaluation (n=50)
6, conclusion
Treatment group 1, treatment group 2, treatment group 3 are treated respectively three courses for the treatment of (10 days each courses for the treatment of) with matched group, treatment group 1 fasting glucose reaches after the meal, and 2 hours blood glucose total effective rates are 98%, treatment group 2 fasting glucose reach after the meal, and 2 hours blood glucose total effective rates are 94%, treatment group 3 fasting glucose and after the meal 2 hours blood glucose total effective rates be 92%, matched group fasting glucose and 2 hours blood glucose total effective rates 84% after the meal.Treatment group of the present invention 1 therapeutic effect is best, treatment group 1 of the present invention, treatment group 2 and treat 3 and obviously be better than matched group.
7, discuss
In pharmaceutical composition of the present invention, Ramulus Mori is the twig of moraceae plants Mulberry, has wind-damp dispelling, and the effect of profit joint row aqueous vapor cures mainly anemofrigid-damp arthralgia, spasm of the limbs, beriberi edema, human body pruritus due to wind pathogen.Ootheca Mantidis is the dry ootheca of Mantidae insecticide Chinese mantid, maculated mantis or huge axe dung beetle, and Ootheca Mantidis has the controlling nocturnal emission with astringent drugs reducing urination, and the effect of reinforcing the kidney and supporting YANG is used for emission due to deficiency of the kidney, premature ejaculation, sexual impotence, nebulousurine, leukorrhagia.Fructus Corni is machaka or dungarunga, has liver and kidney tonifying, restrains astringent or styptic treatment for spontaneous sweatingly, and controlling nocturnal emission with astringent drugs reducing urination, leukorrhagia stopping only collapse, hidroschesis, also have the promoting the production of body fluid to quench thirst effect; Be used for the treatment of the soreness of waist and knee joint dizziness and tinnitus, forgetful emission and spermatorrhea, enuresis frequent micturition, the bleeding not during menses menoxenia, the profuse sweating collapse, interior-heat is quenched one's thirst.Herba Dendrobii is the stem of orchid Dendrobium nobile or its multiple congener, has nourishing YIN and clearing away heat, lung moistening nourishing the stomach, strengthening the tendons and bones.Cure mainly the diseases such as consumption of body fluid caused by febrile disease, xerostomia excessive thirst, stomachache retch, the few expectorant of cough.The all medicine merging of crude drug of the present invention have the effects such as blood sugar lowering, blood fat reducing, the change of change blood flow and antioxidation, and the treatment diabetes are had good therapeutical effect, and effect is remarkable, has no side effect.
Embodiment 1 granule
Ramulus Mori 40kg Ootheca Mantidis 80kg
Fructus Corni 40kg Herba Dendrobii 20kg.
Ramulus Mori, Fructus Corni and Herba Dendrobii are added 15 times of amounts of water, soaked 36 hours; With slow fire boiling 2 times, decocted for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge the secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, fried 8 minutes with slow fire, wear into fine powder and above-mentioned thick paste mixing, low-temperature bake 10 hours, the powder that gets dry extract adds dried cream powder 75% ethanol of 2 times of amounts again, be evaporated to the thick paste shape, add 5 times the amount Icing Sugar, add 70% ethanol a little, make soft material, crossing 14 mesh sieves granulates, wet granular is dry under 50 ℃, and dry grain is packed and get final product after 14 mesh sieve granulate.The granule specification: the 3g/ bag, one day 3 times, one time 1 bag.
Embodiment 2 tablets
Ramulus Mori 25kg Ootheca Mantidis 115kg
Fructus Corni 25kg Herba Dendrobii 28kg.
Ramulus Mori, Fructus Corni and Herba Dendrobii are added 15 times of amounts of water, soaked 36 hours; With slow fire boiling 2 times, decocted for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge the secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, fried 8 minutes with slow fire, wear into fine powder and above-mentioned thick paste mixing, low-temperature bake 10 hours, the powder that gets dry extract is crossed 80 mesh sieves with dried cream powder, adds the starch mixing, then adds 10% starch slurry to make soft material, the granulation of sieving adds tabletting after the magnesium stearate mixing, and get final product.Wherein the ratio of mixture A and starch, 10% starch slurry, magnesium stearate is 10:1:0.5:0.05.The tablet specification is: 0.3g/ sheet, every day three times, each 1.
Embodiment 3 capsules
Ramulus Mori 55kg Ootheca Mantidis 45kg
Fructus Corni 55kg Herba Dendrobii 12kg.
Ramulus Mori, Fructus Corni and Herba Dendrobii are added 12 times of amounts of water, soaked 38 hours; With slow fire boiling 2 times, decocted for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge the secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, fried 8 minutes with slow fire, wear into fine powder and above-mentioned thick paste mixing, low-temperature bake 10 hours, the powder that gets dry extract, the weight ratio that is 1:0.5 with dried cream powder and starch adds adjuvant, granulation, 50 ℃ of dryings are sub-packed in capsule after granulate.The capsule specification: the 0.2g/ grain, one day 3 times, one time 1.
Claims (8)
1. a pharmaceutical composition for the treatment of diabetes, is characterized in that, said composition is made by following raw material medicaments:
Ramulus Mori 20-60 weight portion Ootheca Mantidis 40-120 weight portion
Fructus Corni 20-60 weight portion Herba Dendrobii 10-30 weight portion.
2. pharmaceutical composition as claimed in claim 1, is characterized in that, said composition is made by following raw material medicaments:
Ramulus Mori 40 weight portion Ootheca Mantidis 80 weight portions
Fructus Corni 40 weight portion Herba Dendrobii 20 weight portions.
3. pharmaceutical composition as claimed in claim 1, is characterized in that, said composition is made by following raw material medicaments:
Ramulus Mori 25 weight portion Ootheca Mantidis 115 weight portions
Fructus Corni 25 weight portion Herba Dendrobii 28 weight portions.
4. pharmaceutical composition as claimed in claim 1, is characterized in that, said composition is made by following raw material medicaments:
Ramulus Mori 55 weight portion Ootheca Mantidis 45 weight portions
Fructus Corni 55 weight portion Herba Dendrobii 12 weight portions.
5. pharmaceutical composition as described in one of claim 1-4, is characterized in that this pharmaceutical composition adds conventional adjuvant to make the tablet of clinical acceptance, granule, capsule, pill or oral liquid according to common process.
6. as the preparation method of one of claim 1-4 described pharmaceutical composition, it is characterized in that, this preparation method is: Ramulus Mori, Fructus Corni and Herba Dendrobii are added water 10-20 doubly measure, soaked 24-48 hour; With slow fire boiling 1-3 time, decocted 1-3 hour at every turn, medicinal liquid is leached, collect standby; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, fried 5-10 minute with slow fire, wear into fine powder and above-mentioned thick paste mixing, low-temperature bake 5-15 hour, the powder that gets dry extract added conventional adjuvant pharmaceutically to make tablet, capsule, granule, oral liquid, injection or pill dried cream powder.
7. the preparation method of pharmaceutical composition as claimed in claim 6, is characterized in that, this preparation method is: Ramulus Mori, Fructus Corni and Herba Dendrobii are added 15 times of amounts of water, soaked 36 hours; With slow fire boiling 2 times, decocted for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge the secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, fried 8 minutes with slow fire, wear into fine powder and above-mentioned thick paste mixing, low-temperature bake 10 hours, the powder that gets dry extract adds dried cream powder 75% ethanol of 2 times of amounts again, be evaporated to the thick paste shape, add 5 times the amount Icing Sugar, add 70% ethanol a little, make soft material, crossing 14 mesh sieves granulates, wet granular is dry under 50 ℃, and dry grain is after 14 mesh sieve granulate, granulation agent.
8. the application of pharmaceutical composition as described in one of claim 1-4 in the medicine of preparation treatment diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310053437.7A CN103110825B (en) | 2013-02-19 | 2013-02-19 | Medicinal composition for treating diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310053437.7A CN103110825B (en) | 2013-02-19 | 2013-02-19 | Medicinal composition for treating diabetes and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103110825A true CN103110825A (en) | 2013-05-22 |
| CN103110825B CN103110825B (en) | 2014-08-20 |
Family
ID=48409232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310053437.7A Active CN103110825B (en) | 2013-02-19 | 2013-02-19 | Medicinal composition for treating diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110825B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154255A (en) * | 1996-01-11 | 1997-07-16 | 严跃华 | Capsulized traditional Chinese proprietary medicine- |
| CN1173337A (en) * | 1995-04-18 | 1998-02-18 | 申志荣 | Granules medicament for effecting a radical cure of three types of diabetes |
| CN102631526A (en) * | 2011-02-14 | 2012-08-15 | 王宇红 | Chinese medicinal composition for treating diabetes mellitus |
-
2013
- 2013-02-19 CN CN201310053437.7A patent/CN103110825B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1173337A (en) * | 1995-04-18 | 1998-02-18 | 申志荣 | Granules medicament for effecting a radical cure of three types of diabetes |
| CN1154255A (en) * | 1996-01-11 | 1997-07-16 | 严跃华 | Capsulized traditional Chinese proprietary medicine- |
| CN102631526A (en) * | 2011-02-14 | 2012-08-15 | 王宇红 | Chinese medicinal composition for treating diabetes mellitus |
Non-Patent Citations (2)
| Title |
|---|
| 康小明: "古瓦汤合补脾胃泻阴火升阳汤加味治疗2 型糖尿病86例", 《陕西中医》 * |
| 邱若旗; 王桂玲: "自拟抑肝降糖灵配合食疗治疗糖尿病", 《中国社区医师(综合版)》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103110825B (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100531793C (en) | Chinese medicinal composition for treating pain and preparation process thereof | |
| CN104366636B (en) | A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application | |
| CN101708295A (en) | Chinese medicinal preparation for treating diabetes and preparation methods thereof | |
| CN100443111C (en) | A Chinese traditional medicine for treatment of hemorrhoid, anal fistula and anal fissure and their preparation methods | |
| CN101757591B (en) | Traditional Chinese medicine composition for treating chronic colitis and protitis | |
| CN101897879B (en) | Traditional Chinese medicine for treating rheumatic arthritis | |
| CN101537160B (en) | Health product for toxicant elimination and beauty maintenance | |
| CN105125885B (en) | It is a kind of to be used to prevent Chinese medicine composition of diabetes and preparation method thereof | |
| CN101474258B (en) | Ficus microcarpa var.pusillifolia extract, extracting method and application of the extract | |
| CN103110825B (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN1726964A (en) | Chinese materia medica preparation for curing fracture and traumatic injury | |
| CN103099849B (en) | Medicinal composition for treatment of diabetes, preparation method and new application thereof | |
| CN102218131B (en) | External Chinese herbal medicine composition for promoting tissue regeneration and knitting bones | |
| CN103110698B (en) | Traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN103110862B (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN103110721A (en) | Medicinal composition for treating diabetes | |
| CN100484561C (en) | Medicament composition for treating ulcer in alimentary canal and preparation method | |
| CN114470114B (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
| CN100584364C (en) | A blood circulation-invigorating tendon-strengthening capsule and preparation process thereof | |
| CN102335392B (en) | Rhizoma smilacis chinensis dispersion tablet and preparing process thereof | |
| CN101112562B (en) | Chinese traditional medicine composition for treating hyperosteogeny | |
| CN100577195C (en) | Application of Chinese medicine composiiton in preparing medicine for treating salpingitis, oophoritic cyst, colpitis and cervicitis | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN101843738A (en) | Chinese medicament for treating diabetic feet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 266103 Qingdao economic and Technological Development Zone, unity Road, No. 3601, Shandong Applicant after: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. Address before: 266103 Haier Road, Shandong, Qingdao, No. 1 Applicant before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee after: Zhengda Pharmaceutical (Qingdao) Co., Ltd. Address before: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |